Dato-DXd Outperforms Docetaxel in Previously Treated, Advanced NSCLC

Patients with previously treated, advanced NSCLC had longer progression-free survival with Dato-DXd than with docetaxel in a phase 3 study.

Related Keywords

California ,United States ,Los Angeles ,Daiichi Sankyo ,Aaron Lisberg ,University Of California ,